Bibiana Campos-Seijo

This month's editor's comment.

The Romanian pharmacetuical market has grown significantly in recent years, but with stagnation on the horizon, a path forward is needed.

January was another very bleak month financially, but luckily it ended on a bit of a political high...

Christmas is over. Everybody is back at work feeling a bit hungover, a lot poorer and alarmingly heavier...

The first 2 weeks of October witnessed the closure of CPhI (30 September–2 October) and the whole of Biotechnica (7–9 October). Pharmaceutical Technology Europe had a presence at both events, which took place in Frankfurt and Hanover (both Germany), respectively. With record-breaking numbers of attendees, roundtables and conferences of the highest quality, and exhibitors from bio and pharma companies from all over the world, these two events are a must in the calendars of many in the biotech and pharmaceutical industries.

Nanoparticles can also cross the blood–brain barrier, which could make them useful for delivering drugs that target brain tumours or diseases that affect the central nervous system.

Counterfeiting has become the topic of conversation at all levels of the pharmaceutical industry. Considering the rising number of cases, this is hardly surprising.

It's back to school. Another summer has flown past and here we all meet again, ready to return to work and face the winter with renewed energies. Welcome back!

As summer approaches, the European pharmaceutical industry is preparing for a well-deserved break. However, some will leave the arena on a higher note than others. While big pharma is embracing the globalization of the industry and suffering under extreme pressure to improve performance, the biopharmaceutical sector retires with a smile and reasons to celebrate.

On 7–9 May I attended ERBI's Biopartnering Exchange in Cambridge (UK), an event that brought together national and international entrepreneurs, senior executives and industry experts of the biotechnology sector.

One of the headlines before going to print was 'Pfizer earnings suffer as patent expiries cause damage'. This US pharma giant has reported a net income decline of 18% for the first quarter, despite the positive impact of the favourable currency rates.

It is the end of an era. Building on more than 6 years of dedication and hard work, Gurminder Marwaha has left Pharmaceutical Technology Europe (PTE) in search of new challenges. As his successor, I would like to join all the members of the editorial team in wishing him every success.